Weekly paclitaxel treatment of patients with progressive platinum resistant epithelial ovarian cancer.

被引：0
|
作者：
Le, T [1 ]
Baines, KA [1 ]
Rambout, L [1 ]
Rezaifer, P [1 ]
Al Hayki, M [1 ]
Hopkins, L [1 ]
Fung, MFK [1 ]
机构：
[1] Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：488S / 488S
页数：1
相关论文
共 50 条
  • [41] OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
    McNeish, I. A.
    Moreno, V.
    Jayson, G.
    Roxburgh, P.
    Barretina Ginesta, M. P.
    Garcia-Donas, J.
    Anton Torres, A.
    Michael, A.
    Brown, R.
    Krige, D.
    Bendall, J.
    Di Genova, G.
    McElwaine-Johnn, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 421 - 421
  • [42] Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients
    Bruzzone, M
    Catsafados, E
    Miglietta, L
    Amoroso, D
    Pedulla, F
    Giannessi, PG
    Locatelli, MC
    DAntona, A
    Foglia, G
    Mammoliti, S
    Turno, F
    Gentile, A
    Nicosia, F
    Luporini, G
    Ragni, N
    Boccardo, F
    ONCOLOGY, 1996, 53 (05) : 349 - 353
  • [43] Role of weekly paclitaxel in the treatment of advanced ovarian cancer
    Thomas, H
    Rosenberg, P
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 44 : S43 - S51
  • [44] A phase I study of a hypomethylating agent azacitidine in combination with carboplatin in patients with platinum resistant epithelial ovarian cancer.
    Fu, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 277S - 277S
  • [45] Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer
    Watanabe, Y
    Nakai, H
    Ueda, H
    Hoshiai, H
    GYNECOLOGIC ONCOLOGY, 2005, 96 (02) : 323 - 329
  • [46] Effect of topotecan on serum CA-125 in patients with paclitaxel - and platinum-resistant, advanced epithelial ovarian cancer
    Nielsen, H
    Nielsen, D
    Aa, S
    ANNALS OF ONCOLOGY, 1998, 9 : 72 - 72
  • [47] THE ROLE OF PEGYLATED LIPOSOMAL DOXORUBICIN AND WEEKLY PACLITAXEL IN PROLONGING THE PLATINUM-FREE INTERVAL IN EPITHELIAL OVARIAN CANCER
    El-Modir, A.
    Anwar, M. S.
    Doyle, Y.
    Fernando, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 671 - 671
  • [48] INNOVATE-3: Phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.
    Kirson, Eilon David
    Giladi, Moshe
    Bomzon, Zeev
    Weinberg, Uri
    Farber, Ori
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Weekly cisplatin and oral etoposide for platinum resistant ovarian cancer
    Clive, S
    Storey, DJ
    Cullen, C
    Dixon, N
    Rye, T
    MacKean, M
    Smyth, JF
    Gabra, H
    BRITISH JOURNAL OF CANCER, 2004, 91 : S40 - S40
  • [50] Imatinib mesylate with weekly paclitaxel, a feasible regimen for treatment of recurrent epithelial ovarian cancer (rEOC).
    Borgato, L.
    Safra, T.
    Levinson, B.
    Pothuri, J.
    Hope, J.
    Curtin, J.
    Andreopoulou, E.
    Muggia, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345